Response to and Survival after First-Line FOLFIRINOX or Gemcitabine/Nab-Paclitaxel for Localized Pancreatic Ductal Adenocarcinoma. (2021) - Perri, G.; Prakash, L.; Varadhachary, G.R.; Koay, E.J.; Kim, M.; Ikoma, N.; Tzeng, C.; Lee, J.E.; Katz, M.H.